News

Trill Impact has closed its inaugural Ventures Fund, focusing on improved health and climate action

The closing enables continued growth for Trill Impact’s Ventures portfolio, backing innovative companies...

Trading in Trill Impact’s portfolio company Cinclus Pharma commences on Nasdaq Stockholm

The Swedish biopharmaceutical company has successfully raised capital for Phase 3 clinical development

Trill Impact Ventures co-leads USD 25 million series B financing round in May Health

Advancing novel treatment for women suffering from Polycystic Ovary Syndrome related infertility.

Life Science Impact day

Is everything in life science impact investing and if not, how can it be defined and measured?

TT medic joins forces with Trill Impact to accelerate growth

The MedTech development and manufacturing partner for high-quality polymer components, has entered a...

Trill Impact has been awarded as Best ESG Investment Fund: Private Equity

BlueMark has independently verified Trill Impact’s alignment with the Operating Principles for Impact Management

For the second time, BlueMark has independently verified Trill Impact’s alignment with the Operating...

Impact series

We´re excited to share that our Impact Champion Program is back for its second season.

Trill Impact continues to grow

We are excited to now take another step in our growth journey, by welcoming nine talented new hires.

Trill Impact Ventures co-leads the USD 50m financing round in Open Cosmos Ltd.

Multi-sensor satellites and data analytics to support achievement of the SDGs and democratize access...

Impact series

Trill Impact joins the Net Zero Asset Managers initiative.

Trill Impact’s portfolio company tado° announces additional secured funding, bringing the latest round to 55 million Euros

tado° announces further funding from S2G Ventures, alongside 43 million euros from earlier this year,...